SumithiraVasuMD
Hematology • Columbus, OHBlood Banking & Transfusion Medicine, Hematologic Oncology
Assistant Professor, Internal Medicine, Ohio State University COM
Dr. Vasu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-8619Fax+1 614-293-6420
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011- National Institutes of Health Clinical CenterFellowship, Blood Banking/Transfusion Medicine, 2006 - 2008
St Vincent HospitalResidency, Internal Medicine, 2003 - 2006
Thanjavur Medical CollegeClass of 2001
Certifications & Licensure
OH State Medical License 2011 - 2025
MD State Medical License 2006 - 2011
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- The PUMA Trial is a Trial of a Single ProHema Modulated-Cord Blood (CB) Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies. Start of enrollment: 2012 Jul 01
- Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Start of enrollment: 2020 Jan 10
- Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Start of enrollment: 2020 Nov 07
- Join now to see all
Publications & Presentations
PubMed
- Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT.Zachariah DeFilipp, Haesook T Kim, Laura W Knight, Suzanne M O'Connor, Shilton E Dhaver
Blood. 2025-03-19 - Second primary malignancies following CAR T-cell therapy in patients with hematologic malignancies.Elvira Umyarova, Charles Pei, William Pellegrino, Qiuhong Zhao, Nidhi Sharma
Journal of Hematology & Oncology. 2025-03-18 - Efficacy of first-line tagraxofusp in blastic plasmacytoid dendritic cell neoplasm with prior or concomitant hematologic malignancy: subgroup analysis of a pivotal trial.Naveen Pemmaraju, Marina Konopleva, Kendra L Sweet, Anthony S Stein, David A Rizzieri
Leukemia & Lymphoma. 2025-03-11
Abstracts/Posters
- Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell TransplantationSumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...Sumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant AbstractSumithira Vasu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Genomic Features of AML in Patients over Age 60 Can Predict Success of Bone Marrow Stem Cell Transplant, Research ShowsDecember 6th, 2019
Ruxolitinib + Allogeneic Stem Cell Transplantation in AMLSeptember 18th, 2017
Grant Support
- Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignanciesOHIO STATE UNIVERSITY2023–2028
- MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantationOHIO STATE UNIVERSITY2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
